March 16, 2016
Written by Kelley Lennon
SA that looks at the private sector response to PrEP. Aspen, the local manufacturer of Truvada announced a coming cut in the price of the drug (from R550 to R480 a month). A enior executive is quoted: “You cannot place the entire burden and funding of preventing HIV on the public sector.” The story also notes, “Dr Jonathan Broomberg, CEO of Discovery Health, said it would work closely with the HIV Clinicians Society to develop criteria for identification of members who would benefit from Truvada. ‘Once these criteria have been developed we will recommend that our client medical schemes provide funding for Truvada for high-risk individuals,’ Broomberg said.” Discovery Health is a large insurance company in SA (and a major local partner for AIDS2016).